Depuy Hip Replacements

Top Johnson & Johnson officials try to reassure shareholders

During Johnson & Johnson’s annual meeting, outgoing CEO Bill Weldon and successor Alex Gorsky both tried to reassure shareholders that the company is getting its act together, the Washington Post reports.

According to the Washington Post, shareholders were “upset over the health giant’s battered image amid unprecedented product recalls and ethical lapses.”

Weldon told them that the company started growing again last year after two years of sales declines, with revenue climbing ...

continue reading...

Article says FDA approval process is flawed

In a recent article titled “Four Medical Implants that Escaped FDA Scrutiny,” Scientific American takes a critical look at a U.S. Food and Drug Administration approval process that allows dangerous medical devices to be sold in the United States.

The article states that the rate of recalls, faulty devices, and repeat surgeries is increasing in an industry worth over $100 billion per year.

The first two devices the articles spotlights are ...

continue reading...

Mayo Clinic gives information on hip implants

According to the Mayo Clinic, hip replacement surgery is meant to relieve pain and to increase the mobility and function of a damaged hip joint.

But doctors may recommend other treatment first, including pain medication, physical therapy, exercise and the use of a cane or a walker.

The clinic’s Website says the following conditions might make surgery necessary:

  • Osteoarthritis
  • Rheumatoid arthritis
  • Broken hip
  • Bone tumor
  • Osteonecrosis, which occurs when there is inadequate blood supply to the ...
continue reading...

FDA issues guidelines for medical devices

The U.S. Food and Drug Administration has issued what the agency is describing as a “first-of-a-kind guidance” to help medical device manufacturers get through the review process for new devices.

The FDA is issuing the document, titled “Factors To Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications,” to address problems that have come up recently as a result of the agency’s approval process.

An FDA spokeswoman has been quoted as saying: “The devices center identified several ...

continue reading...

Group says legislation ignores FDA loophole

According to a news release by the Consumers Union, a Senate committee is scheduled to discuss legislation that would fail to correct a loophole allowing dangerous medical devices to make it onto the market.

The Consumers Union is the policy and advocacy arm of Consumer Reports.

On April 25, the Senate Health, Education, Labor and Pensions Committee was scheduled to mark-up legislation to reauthorize the Food and Drug Administration Safety and ...

continue reading...

Blog: $1.2b J&J fine for Risperdal deceptive marketing likely to cause further problems

A post on stock market information Website Seeking Alpha says Johnson & Johnson will likely deal with significant public backlash going forward. An Arkansas jury recently concluded that the company used deceptive tactics to market antipsychotic drug Risperdal, which included hiding or minimizing the drug’s risks. A judge then issued a $1.2 billion fine.

The post says the fine leveled against Johnson and Johnson and subsidiary Janssen Pharmaceuticals is the largest ...

continue reading...
Page 27 of 32 «...10202526272829...»